ClinConnect ClinConnect Logo
Search / Trial NCT05851989

Study on Prognosis of Acutely Ruptured Intracranial Aneurysms

Launched by HAAGLANDEN MEDICAL CENTRE · May 1, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Aneurysmal Subarachnoid Hemorrhage Clipping Neurosurgery Coiling Endovascular Treatment Outcome Modified Rankin Scale

ClinConnect Summary

The SPARTA study is a research project happening in the Netherlands that aims to find out the best ways to treat patients with a specific type of bleeding in the brain called aneurysmal subarachnoid hemorrhage. This bleeding is usually caused by a burst blood vessel in the brain known as an aneurysm. The study will compare two main treatment methods: surgery and a less invasive approach called endovascular treatment. Researchers will also look at how much these treatments cost and what factors might influence a patient’s recovery.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of subarachnoid hemorrhage, with a specific aneurysm identified as the cause within the last six months. Participants will be asked to give their written consent to join the study. It’s important to note that the study is currently recruiting participants, and those who are fluent in Dutch are eligible. By joining, participants can help researchers better understand how to improve care for future patients facing this serious condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Confirmed diagnosis of subarachnoid haemorrhage on CT-scan or lumbar puncture (in the presence of a negative CT-scan)
  • Intracranial aneurysm proven within 6 months to be the cause of subarachnoid haemorrhage
  • Age 18 years or over at presentation.
  • Written informed consent
  • Exclusion Criteria:
  • Subarachnoid haemorrhage deemed most likely of 'perimesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)
  • Subarachnoid haemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)
  • Diagnosis of intracerebral arteriovenous malformations or dural arteriovenous fistula.
  • No diagnosis of intracranial aneurysm at 6 months after onset of symptoms.
  • Not mastering the Dutch language

About Haaglanden Medical Centre

Haaglanden Medical Centre is a leading healthcare institution in the Netherlands, dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on collaboration and excellence, the centre integrates clinical practice with cutting-edge research, focusing on a wide range of therapeutic areas. Haaglanden Medical Centre is committed to ensuring the highest ethical standards and regulatory compliance in its research initiatives, fostering an environment that promotes scientific inquiry and enhances the quality of healthcare delivery. Through its multidisciplinary approach and state-of-the-art facilities, the centre aims to contribute significantly to the development of new treatments and therapies for diverse patient populations.

Locations

Rotterdam, , Netherlands

Utrecht, , Netherlands

Maastricht, , Netherlands

Nijmegen, , Netherlands

Amsterdam, , Netherlands

Den Haag, , Netherlands

Patients applied

0 patients applied

Trial Officials

Wouter Moojen, MD, PhD

Principal Investigator

Haaglanden Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported